Alvotech

As of June 30, 2026, Alvotech carries a market capitalization of 169.84B, placing it among publicly traded companies globally. Its enterprise value stands at 334.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alvotech's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Alvotech has 356.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.45, and the price-to-book ratio stands at -7.05.

As of June 30, 2026, Alvotech trades at an EV/EBITDA multiple of 29.92 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 55.93 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 334.59B versus a market cap of 169.84B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Alvotech maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -758.20, indicating conservative leverage, while an interest coverage ratio of 0.62 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -12.05, reflecting losses generated across the asset base. The company generates approximately 45.76M in revenue per employee across its workforce of 1,353.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.02 indicates how many times Alvotech sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Alvotech recorded 18.55B in income tax expense. The company reported a pretax loss of -4.05B and -22.60B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Alvotech's stock has declined approximately 40.00% over the past 52 weeks. The 50-day moving average sits at 641.84, while the 200-day moving average is 524.02.

Over the twelve months ended June 30, 2026, Alvotech generated 61.91B in revenue and converted that into -22.60B in net income, yielding earnings per share of -70.86. EBITDA reached 11.18B, while operating income came in at 5.98B.

As of June 30, 2026, Alvotech holds 17.97B in cash and equivalents against 182.71B in total debt, resulting in a net debt position of 146.40B. Total book value stands at -24.10B, with working capital of 26.91B providing operational flexibility.

Alvotech produced -25.01B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -17.01B in capital expenditures, free cash flow totaled -42.01B - equivalent to -131.71 per share.

Over the twelve months ended June 30, 2026, Alvotech posted a gross margin of 60.45, reflecting its pricing power and cost economics. The operating margin of 9.66 and net profit margin of -36.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -27.67: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.89, meaning Alvotech raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Alvotech has an Altman Z-Score of -1.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.